Screening for Asymptomatic Osteonecrosis of the Hip in Systemic Lupus Erythematous: A Systematic Review and Meta-Analysis of MRI-Based Prevalence

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2024 Feb 10

PMID 38337795

Authors

Hamza A Ibad

Elena Ghotbi

Arta Kasaeian

Adam S Levin

Lynne C Jones

Yoshimi Anzai

Maryam Soltanolkotabi

Neena Kapoor

Pamela T Johnson

Shadpour Demehri

Affiliations

Soon will be listed here.

Abstract

. This paper aims to estimate asymptomatic hip osteonecrosis prevalence in SLE patients using MRI examination and to determine the prevalence among higher risk subpopulations. . PubMed, Embase, Cochrane, and SCOPUS were searched from inception to May 9th, 2023. Studies on patients who were clinically diagnosed with systemic lupus erythematosus without reported symptoms attributable to hip osteonecrosis were included. Two independent reviewers extracted data and assessed the risk of bias. Data collected from each study include the study year, the number of hips screened, the number of hips with osteonecrosis, demographics, laboratory data, medications, follow-up time, radiological protocols, and MRI-based osteonecrosis detection and grading criteria. . Eleven eligible studies including 503 participants (15-35 years old; 74-100% female) with SLE were identified. Significant risk of bias was determined in one study. The overall prevalence of osteonecrosis of the hip was found to be 14% (184/1006 hip joints, 95% confidence interval: 7-22%, number needed to scan: 7.1). SLE patients who received corticosteroid treatment had a higher prevalence of asymptomatic hip osteonecrosis (18%) compared to non-corticosteroid users (0%, -value < 0.01). Additionally, meta-regression results revealed that daily corticosteroid dose was associated with increased prevalence of asymptomatic osteonecrosis (0.5%/milligram, -value < 0.01). . The high prevalence of asymptomatic hip osteonecrosis in SLE patients raises concerns about the timeliness of interventions. The limitations of this study include a relatively low number of identified studies; and one study lacked full-text availability.

References

Nakamura J, Harada Y, Oinuma K, Iida S, Kishida S, Takahashi K . Spontaneous repair of asymptomatic osteonecrosis associated with corticosteroid therapy in systemic lupus erythematosus: 10-year minimum follow-up with MRI. Lupus. 2010; 19(11):1307-14. DOI: 10.1177/0961203310372951. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

Jaovisidha S, Denprechawong R, Suwannalai P, Janwityanujit S . Asymptomatic avascular osteonecrosis of the hip in new patients diagnosed as systemic lupus erythematosus in Ramathibodi Hospital. J Med Assoc Thai. 2007; 90(7):1382-90. View

Sugano N, Takaoka K, Ohzono K, Matsui M, Masuhara K, Ono K . Prognostication of nontraumatic avascular necrosis of the femoral head. Significance of location and size of the necrotic lesion. Clin Orthop Relat Res. 1994; (303):155-64. View

Gordon C, Amissah-Arthur M, Gayed M, Brown S, Bruce I, DCruz D . The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2017; 57(1):e1-e45. DOI: 10.1093/rheumatology/kex286. View

Nawata K, Nakamura J, Ikeda K, Furuta S, Nakajima H, Ohtori S . Transitional changes in the incidence of osteonecrosis in systemic lupus erythematosus patients: focus on immunosuppressant agents and glucocorticoids. Rheumatology (Oxford). 2018; 57(5):844-849. DOI: 10.1093/rheumatology/key009. View

Castro T, Lederman H, Terreri M, Caldana W, Kaste S, Hilario M . The use of joint-specific and whole-body MRI in osteonecrosis: a study in patients with juvenile systemic lupus erythematosus. Br J Radiol. 2010; 84(1003):621-8. PMC: 3473496. DOI: 10.1259/bjr/34972239. View

Kuroda T, Tanabe N, Wakamatsu A, Takai C, Sato H, Nakatsue T . High triglyceride is a risk factor for silent osteonecrosis of the femoral head in systemic lupus erythematosus. Clin Rheumatol. 2015; 34(12):2071-7. DOI: 10.1007/s10067-015-3075-y. View

Nagasawa K, Tada Y, Koarada S, Tsukamoto H, Horiuchi T, Yoshizawa S . Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant. Lupus. 2006; 15(6):354-7. DOI: 10.1191/0961203306lu2311oa. View

10.

Hungerford D, Jones L . Asymptomatic osteonecrosis: should it be treated?. Clin Orthop Relat Res. 2004; (429):124-30. View

11.

Oh S, Jee W, Cho S, Kim S, Kang H, Ryu K . Osteonecrosis in patients with systemic lupus erythematosus: MR imaging and scintigraphic evaluation. Clin Imaging. 2004; 28(4):305-9. DOI: 10.1016/S0899-7071(03)00192-X. View

12.

Izmirly P, Parton H, Wang L, McCune W, Lim S, Drenkard C . Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021; 73(6):991-996. PMC: 8169527. DOI: 10.1002/art.41632. View

13.

Nakamura J, Saisu T, Yamashita K, Suzuki C, Kamegaya M, Takahashi K . Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study. Arthritis Rheum. 2010; 62(2):609-15. DOI: 10.1002/art.27236. View

14.

Klippel J, Gerber L, Pollak L, Decker J . Avascular necrosis in systemic lupus erythematosus. Silent symmetric osteonecroses. Am J Med. 1979; 67(1):83-7. DOI: 10.1016/0002-9343(79)90077-9. View

15.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007; 370(9596):1453-7. DOI: 10.1016/S0140-6736(07)61602-X. View

16.

Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C . Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012; 65(9):934-9. DOI: 10.1016/j.jclinepi.2011.11.014. View

17.

Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis J . 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019; 78(6):736-745. DOI: 10.1136/annrheumdis-2019-215089. View

18.

Sayarlioglu M, Yuzbasioglu N, Inanc M, Kamali S, Cefle A, Karaman O . Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int. 2010; 32(1):177-82. DOI: 10.1007/s00296-010-1597-9. View

19.

Hernigou P, Habibi A, Bachir D, Galacteros F . The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease. J Bone Joint Surg Am. 2006; 88(12):2565-72. DOI: 10.2106/JBJS.E.01455. View

20.

Nagasawa K, Tada Y, Koarada S, Horiuchi T, Tsukamoto H, Murai K . Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus. 2005; 14(5):385-90. DOI: 10.1191/0961203305lu2103oa. View